Institutional Biosafety Committee (IBC)
On behalf of Cleveland Clinic, the Institutional Biosafety Committee (IBC) is responsible for reviewing recombinant and synthetic nucleic acid molecule research for compliance with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIHG).
In compliance with guidance from the National Institutes of Health's Office of Science Policy (OSP), meeting minutes subject to the NIHG and taking place on, or after June 1, 2025 will be added to this page on a rolling basis.
Members of the public who would like to learn more about an IBC should contact [email protected] or [email protected].